Pharmaceutical News

RSS

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.

11 Nov 2014

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost. Doctoral researcher Diederik De Cock (KU Leuven) describes the strategy in a new study published in Annals of Rheumatic Diseases.

11 Nov 2014

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin (trade name: Halaven) is approved for women with locally advanced or metastatic breast cancer in whom the disease has progressed despite prior drug therapy. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups.

7 Nov 2014

Health benefits of modified formulation of curcumin supplements

The health benefits of over-the-counter curcumin supplements might not get past your gut, but new research shows that a modified formulation of the spice releases its anti-inflammatory goodness throughout the body.

7 Nov 2014

Zinc supplements more beneficial for some people with diabetes

Researchers at the Johns Hopkins University School of Medicine and elsewhere have found that genetic differences may account for why zinc supplements are more beneficial to some people than to others for the prevention and control of diabetes. The results of their pilot study of a population of Old Order Amish is believed to be the first to point out the relevance of small genetic differences in response to zinc supplementation at play in diabetes management.

7 Nov 2014

Osteoporosis drugs may also benefit patients with tumours outside the skeleton

Australian researchers have shown why calcium-binding drugs commonly used to treat people with osteoporosis, or with late-stage cancers that have spread to bone, may also benefit patients with tumours outside the skeleton, including breast cancer.

6 Nov 2014

MMRF initiative aims to speed up evaluation of new investigational drugs for multiple myeloma

The Multiple Myeloma Research Foundation today announced an initiative designed to accelerate the evaluation of new investigational therapies for multiple myeloma (MM).

6 Nov 2014

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.

6 Nov 2014

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

The National Institutes of Health has boosted funding for the first large-scale clinical trial aimed at identifying drugs to stop or slow Alzheimer's disease in people destined to get the debilitating illness.

6 Nov 2014

Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax Laboratories (Netherlands) B.V., a wholly owned subsidiary of Impax Laboratories, Inc. today announced that it has submitted a Marketing Authorization Application for IPX066 to the European Medicines Agency. IPX066 is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease.

6 Nov 2014

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Based on its recent analysis of the pharmaceutical drug delivery industry, Frost & Sullivan recognizes Acino Pharma AG with the 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership. Acino's expertise in targeted drug release profiles and strong technical know-how in pellet-coating, transdermal therapeutic patches and biodegradable implants has made it the preferred vendor in contract manufacturing.

6 Nov 2014

Perrigo re-launches shipments of Guaifenesin 600mg Extended-Release tablets

Perrigo Company plc announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex 600mg Extended-Release tablets.

6 Nov 2014

AZD3965 drug inhibits growth of tumours in the lab

Manchester scientists have shown that a new drug inhibits the growth of tumours in the lab and that its effectiveness is improved by combining it with radiotherapy - suggesting a new approach that could be used in the clinic.

6 Nov 2014

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Murdoch University researchers from the Centre for Comparative Genomics have received almost $800,000 in funding from the National Health and Medical Research Council to develop genetic drugs to treat rare diseases.

6 Nov 2014

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Commonly prescribed drugs for arthritis and pain may increase risk of death from stroke

Commonly prescribed, older drugs for arthritis and pain may increase the risk of death from stroke, according to a study published in the November 5, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. Stroke is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

5 Nov 2014

Hospira launches Paricalcitol Injection

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.

5 Nov 2014

ProstaCaid dietary supplement supports prostate health

A recent presentation at an international cancer research conference in Greece reviewed the body of data on ProstaCaid, a dietary supplement compound for prostate health. A number of published studies demonstrate the formula's effects in supporting prostate health against specific prostate cancer cell lines and prostate urinary symptoms.

5 Nov 2014

Dietary supplement KoACT is superior to calcium, vitamin D for bone health, study reveals

A new study by a Florida State University researcher reveals that a new dietary supplement is superior to calcium and vitamin D when it comes to bone health.

5 Nov 2014

Pharmaceutical News

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

New drug combination shows promise as effective, safe treatment for rheumatoid arthritis

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Health benefits of modified formulation of curcumin supplements

Zinc supplements more beneficial for some people with diabetes

Osteoporosis drugs may also benefit patients with tumours outside the skeleton

MMRF initiative aims to speed up evaluation of new investigational drugs for multiple myeloma

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

Impax announces submission of EMA Marketing Authorization Application for IPX066

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Perrigo re-launches shipments of Guaifenesin 600mg Extended-Release tablets

AZD3965 drug inhibits growth of tumours in the lab

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Commonly prescribed drugs for arthritis and pain may increase risk of death from stroke

Hospira launches Paricalcitol Injection

ProstaCaid dietary supplement supports prostate health

Dietary supplement KoACT is superior to calcium, vitamin D for bone health, study reveals

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News